Company & Sponsor Intelligence
Neurim Pharmaceuticals Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT02615002Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT05267535Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
alzheimers · United StatesPHASE2, PHASE3
alzheimers · United StatesPHASE2, PHASE3
NCT00940589Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →